An approval in Australia and positive recommendations for 2 biosimilars in Europe bring hope for more affordable biologics around the world. However, another settlement for a US ustekinumab biosimilar showcases that some barriers remain.
An approval in Australia and positive recommendations for 2 biosimilars in Europe bring hope for more affordable biologics around the world. However, another settlement for a US ustekinumab biosimilar showcases that some barriers remain.
Celltrion Approval in Australia
Celltrion received approval from the Therapeutic Goods Administration, the equivalent of the FDA in Australia, for its bevacizumab biosimilar (Vegzelma), according to a report from Korea Biomedical Review.
The drug references Avastin and is indicated for metastatic colorectal cancer, non–small cell lung cancer, metastatic renal cell carcinoma, cervical cancer, epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer, and glioblastoma.
Australia is known for having proactive biosimilar-friendly policies and encouraging the prescription of biosimilars. The new approval marks the 44th biosimilar approval for the country and the fifth approval for a bevacizumab biosimilar. Celltrion has 4 other biosimilars in Australia: Remsima (infliximab biosimilar), Herzuma (trastuzumab biosimilar), Truxima (rituximab biosimilar), and Yuflyma (adalimumab biosimilar). The company has also completed an Australian approval application for its ustekinumab candidate referencing Stelara.
Two CHMP Positive Opinions
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued positive opinions for Biocon Biologics’ aflibercept biosimilar (Yesafili) and Sandoz’ natalizumab biosimilar (marketed as Tyruko in the United States).
If approved by the European Commission, the final step in the EU’s approval process, the aflibercept product will treat a number of ophthalmic conditions—including age-related macular degeneration, diabetic retinopathy, and macular edema—and the natalizumab product will be used in relapsing-remitting multiple sclerosis (MS) and Crohn disease.
Sandoz has been working with Polpharma Biologics, a Poland-based biosimilar developer, on the natalizumab candidate, which references Tysabri. Yesafili is a biosimilar referencing Eylea. For comparison, the United States has approved Sandoz’ product as the first MS biosimilar in the country and has yet to approve an aflibercept product.
“Access to affordable, high-quality treatments like disease-modifying therapies—which are a cornerstone in the treatment of multiple sclerosis—remains limited for many people living with this disease,” said Pierre Bourdage, chief commercial officer, Sandoz, in a company statement. Today’s positive opinion from the CHMP is a clear step in the right direction to address the burden of the disease for those living with multiple sclerosis while also delivering savings for health care systems.”
Biocon Biologics said it expects an official approval for Yesafili by the end of September and Sandoz did not disclose when it anticipates a final decision.
Another US Settlement for Stelara Biosimilar
In the United States, Johnson & Johnson (J&J), the maker of Stelara, has accepted another settlement from a biosimilar manufacturer regarding the development of an ustekinumab product—this time with Formycon and Fresenius Kabi, according to Pharmaceutical Technology.
The latest settlement follows J&J’s settlements with Alvotech and Teva Pharmaceuticals, as well as Amgen, delaying the original prediction for US launches for ustekinumab biosimilars from late 2023/early 2024 to 2025. However, while Amgen’s product will be allowed to launch in January 2025, Formycon and Fresenius Kabi will have to wait until at least April 15, 2025.
Ustekinumab products are used to treat patients with moderate to severe plaque psoriasis and psoriatic arthritis.
Data Show Promise for Adalimumab Biosimilars to Deliver on Safety, Cost Savings
May 16th 2024Two posters from the Academy of Managed Care Pharmacy’s annual meeting provided hope that despite low uptake so far, adalimumab biosimilars can deliver on the promise of comparable safety and efficacy with the originator in multiple disease states, as well as cost savings.
Partnering for Biosimilar Security: India's Role in US Health Care Savings, Supply Chain Stability
May 9th 2024As Indian pharmaceutical companies supplied 4 of every 10 prescriptions in the US in 2022, generating $1.3 trillion in health care savings, a new IQVIA report highlights concerns about supply chain risks and advocates for partnerships to bolster biosimilar security and overall supply chain resilience.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Review: Product Attributes Relevant to Injection-Site Pain, Adalimumab Treatment
May 4th 2024A review article summarizes the product attributes of reference and biosimilar adalimumab products, such as formulation with or without citrate, delivery volume, and needle gauge, relevant to patients’ experience of injection-site pain.
Cencora Analysis Shows Differences in Payer Coverage Between G-CSF Biosimilars
May 2nd 2024Data from a Cencora study showed some misalignment in payer coverage of granulocyte colony-stimulating factor (G-CSF) biosimilars, highlighting that while filgrastim biosimilars are often favored over the originator, reference pegfilgrastim still dominates over its biosimilars.